Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | STAT3 | P40763 | 1/20 | 0.60 |
| ▸ | STAT1 | P42224 | 1/20 | 0.60 |
| ▸ | AURKA | O14965 | 1/20 | 0.42 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | VDR | P11473 | 1/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.41 |
| ▸ | CYP2B6 | P20813 | 1/20 | 0.41 |
| ▸ | AHR | P35869 | 1/20 | 0.41 |
| ▸ | NR1I3 | Q14994 | 1/20 | 0.41 |
| ▸ | MAPK13 | O15264 | 1/20 | 0.40 |
| ▸ | RAF1 | P04049 | 1/20 | 0.40 |
| ▸ | MAPK12 | P53778 | 1/20 | 0.40 |
| ▸ | MAPK11 | Q15759 | 1/20 | 0.40 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.40 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.39 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.39 |
| ▸ | DCUN1D1 | Q96GG9 | 1/20 | 0.39 |
| ▸ | PIN1 | Q13526 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL585528 | 0.98 | STAT3 (0.62) | STAT3STAT1AURKANR1I2CYP1A2 | |
| SCHEMBL31055740 | 0.98 | STAT3 (0.62) | STAT3STAT1AURKANR1I2CYP1A2 | |
| SCHEMBL17687652 | 0.96 | STAT3 (0.57) | STAT3STAT1AURKANR1I2CYP1A2 | |
| SCHEMBL2942315 | 0.89 | STAT3 (0.56) | STAT3STAT1MAPK13RAF1MAPK12 | |
| SCHEMBL28166900 | 0.87 | STAT3 (0.51) | STAT3STAT1AURKANR1I2CYP1A2 | |
| SCHEMBL9590030 | 0.86 | STAT3 (0.60) | STAT3STAT1AURKAKDM4ENPC1 | |
| SCHEMBL6804332 | 0.86 | STAT3 (0.59) | STAT3STAT1CYP1A2CYP2C9CYP2B6 | |
| SCHEMBL17687651 | 0.86 | AURKA (0.46) | STAT3STAT1AURKANR1I2CYP1A2 | |
| SCHEMBL8996959 | 0.85 | STAT3 (0.59) | STAT3STAT1AURKAKDM4ENPC1 | |
| SCHEMBL4266558 | 0.84 | STAT3 (0.63) | STAT3STAT1AURKAKDM4ENPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 46 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115403780-A | Photosensitizer material, preparation method and application thereof in preparation of polymer | 合肥工业大学 | 2022-11-29 | — | — | CN | claimed |
| CN-115403780-B | Photosensitizer material, preparation method and application thereof in preparation of polymer | 合肥工业大学 | 2024-06-14 | — | — | CN | disclosed |
| CN-115403780-A | Photosensitizer material, preparation method and application thereof in preparation of polymer | 合肥工业大学 | 2022-11-29 | — | — | CN | disclosed |
| EP-2379109-B1 | COMBINATION OF PHOTODYNAMIC THERAPY AND ANTI-VEGF AGENTS IN THE TREATMENT OF UNWANTED CHOROIDAL NEOVASCULATURE | BAUSCH HEALTH COMPANIES INC (CA) | 2020-10-07 | — | — | EP | disclosed |
| EP-1357912-B9 | PHOTODYNAMIC THERAPY OF OCCULT CHOROIDAL NEOVASCULARIZATION LINKED TO AGE-RELATED MACULAR DEGENERATION | QUADRA LOGIC TECH INC (CA) | 2012-06-13 | — | — | EP | disclosed |
| CN-102325550-A | Combination of photodynamic therapy and anti-VEGF agents in the treatment of unwanted choroidal neovasculature | QUADRA LOGIC TECH INC | 2012-01-18 | — | — | CN | disclosed |
| US-7850981-B2 | Immuno-adjuvant PDT treatment of metastatic tumors | QLT, INC. (CA) | 2010-12-14 | — | — | US | disclosed |
| US-7753943-B2 | Reduced fluence rate PDT | QLT INC. (CA) | 2010-07-13 | — | — | US | disclosed |
| WO-2010069073-A1 | COMBINATION OF PHOTODYNAMIC THERAPY AND ANTI-VEGF AGENTS IN THE TREATMENT OF UNWANTED CHOROIDAL NEOVASCULATURE | QLT INC. (CA) | 2010-06-24 | — | — | WO | disclosed |
| US-20100040546-A1 | Biological targeting compositions and methods of using the same | SEARETE LLC, A LIMITED LIABILITY CORPORATION OF THE STATE OF DELAWARE | 2010-02-18 | — | — | US | disclosed |
| US-6599891-B2 | Administering to the subject an amount of a photosensitizer (PS) sufficient to allow said photosensitizer to localize in lesion; irradiating said lesion with light having a wavelength absorbed by said PS | QLT INC. (CA) | 2003-07-29 | — | — | US | disclosed |
| US-20030099596-A1 | Treatment of macular edema | BAUSCH HEALTH IRELAND LIMITED (IE) | 2003-05-29 | — | — | US | disclosed |
| US-20030087889-A1 | Photodynamic therapy of occult age-related macular degeneration | BAUSCH HEALTH COMPANIES INC. (CA) | 2003-05-08 | — | — | US | disclosed |
| US-20030083649-A1 | Method for reducing or preventing PDT related inflammation | VALEANT SP. Z.O.O. (PL) | 2003-05-01 | — | — | US | disclosed |
| US-20020183302-A1 | Method to prevent vision loss | TECHNOLAS PERFECT VISION GMBH (DE) | 2002-12-05 | — | — | US | disclosed |
| US-20020173832-A1 | Reduced fluence rate PDT | TECHNOLAS PERFECT VISION GMBH (DE) | 2002-11-21 | — | — | US | disclosed |
| US-20020156062-A1 | Drug delivery system for hydrophobic drugs | BAUSCH HEALTH COMPANIES INC. (CA) | 2002-10-24 | — | — | US | disclosed |
| US-20020155089-A1 | Drug delivery systems for photodynamic therapy | UNIVERSITY OF BRITISH COLUMBIA, THE (CA) | 2002-10-24 | — | — | US | disclosed |
| US-20020061330-A1 | Supports for photosensitizer formulations | BRITISH COLUMBIA, THE UNIVERSITY OF (CA) | 2002-05-23 | — | — | US | disclosed |
| US-20020022032-A1 | Immuno-adjuvant PDT treatment of metastatic tumors | QLT INC. (CA) | 2002-02-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030099596-A1 | Treatment of macular edema | VEGFA, PPOX, FLT4 | STAT3 1040/4885STAT1 2481/4885AURKA 2728/4885 |
| US-20020183302-A1 | Method to prevent vision loss | VEGFA, ALDH1A2, PDE6C | STAT3 3671/4885STAT1 4212/4885AURKA 4774/4885 |
| US-20020156062-A1 | Drug delivery system for hydrophobic drugs | LIPA, MLEC, ABCG2 | STAT3 3700/4885STAT1 4562/4885AURKA 2041/4885 |
| US-20020155089-A1 | Drug delivery systems for photodynamic therapy | PIN1, PPOX, DHFR | STAT3 2013/4885STAT1 3494/4885AURKA 958/4885 |
| US-20020061330-A1 | Supports for photosensitizer formulations | PPOX, PPIF, SDHA | STAT3 4556/4885STAT1 4147/4885AURKA 2544/4885 |
| US-20020022032-A1 | Immuno-adjuvant PDT treatment of metastatic tumors | CD74, ANXA11, ANXA1 | STAT3 483/4885STAT1 851/4885AURKA 1900/4885 |
| US-20030087889-A1 | Photodynamic therapy of occult age-related macular degeneration | ALDH1A2, AGER, CRY2 | STAT3 3077/4885STAT1 4250/4885AURKA 1286/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.